Skip to main content Accessibility help
  • Print publication year: 2010
  • Online publication date: December 2010

117 - Novel sustained-release analgesics

from Section 12 - New and Emerging Analgesics


1. GuptaS, SathyanG. Providing constant analgesia with OROS® hydromorphone. J Pain Symptom Manage 2007;33(2):S19–S24.
2. PalangioM, NorthfeltD, PortenoyR, BrookoffD, DoyleR, DornseifB, DamaskM. Dose conversion and titration with a novel, once-daily, OROS® osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage 2002;23(5):355–368.
3. RathboneM, HadgraftJ, RobertsM, LaneM. Modified-Release Drug Delivery Technology, 2nd ed. Vol. 1. New York: Informa Healthcare, 2008.
4. SathyanG, XuE, ThipphawongJ, GuptaSK. Pharmacokinetic profile of the 24-hour controlled release OROS® formulation of hydromorphone in the presence and absence of food. BMC Clin Pharmacol 2007;7:2.
5. SathyanG, XuE, ThipphawongJ, GuptaSK. Pharmacokinetic investigation of dose proportionality with a 24 hour controlled-release formulation of hydromorphone. BMC Clin Pharmacol 2007;7:3.
6. WrightJ, YumS, JohnsonRM. DUROS® Osmotic Pharmaceutical Systems for Parenteral & Site-Directed Therapy. Drug Deliv Technol 2003;3:64–73.